This article first appeared on GuruFocus .
-
Revenue:Increased by 8% to almost EUR 1.4 billion for Q3 2025.
-
EBITA Margin:5.8% for the quarter.
-
Earnings Per Share:Slightly up to EUR 1.47.
-
Free Cash Flow:Improved by close to 30%, from EUR 55 million to EUR 71 million.
-
Orders Received:Increased by 1% to EUR 1.36 billion.
-
Order Backlog:Up by 7%.
-
Net Profit:Remained at EUR 55 million for the quarter.
-
SG&A Ratio:Reduced from 6.1% to 5.8%.
-
Net Trade Assets:Reduced to 8% of revenue.
-
Group Net Liquidity and Leverage:Leverage at about 0.4, below the threshold of 2.
-
Revenue Outlook for Full Year:EUR 5.3 to 5.5 billion.
-
EBITA Margin Outlook for Full Year:5.4% to 5.6%.
-
Free Cash Flow Outlook for Full Year:EUR 300 to 360 million.
Release Date: November 13, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
Positive Points
-
Bilfinger SE ( BFLBF ) reported an 8% increase in revenue for Q3 2025, indicating strong business performance.
-
The company achieved a significant improvement in free cash flow, increasing by nearly 30% from EUR 55 million to EUR 71 million.
-
Bilfinger SE ( BFLBF ) updated its revenue outlook for the year to EUR 5.3 to 5.5 billion, with an EBITA margin of 5.4% to 5.6%, reflecting confidence in future performance.
-
The company has maintained a positive cash flow for nine consecutive quarters, demonstrating financial stability.
-
Bilfinger SE ( BFLBF ) is seeing strong demand in its core industries, particularly in pharma and biopharma, which continue to show growth.
Negative Points
-
The total recordable incident frequency increased from 0.88 to 1.01, indicating a slight decline in safety performance.
-
The chemical and petrochemical sectors are underperforming compared to 2019 levels, particularly in Germany, affecting overall industry performance.
-
The EBITA margin slightly decreased from 6.0% to 5.8%, showing a minor decline in profitability.
-
The company faces challenges in the German market, with the chemical industry experiencing low utilization and high costs.
-
There is a noted slowdown in US government-related business, which may impact future revenue growth in the E&M International segment.
Q & A Highlights
Q: Can you elaborate on the strong opportunity pipeline and the underlying drivers? A: Thomas Schulz, CEO, explained that recent acquisitions have unlocked more potential within existing business lines, allowing Bilfinger to bid on larger service contracts. Additionally, the company plans to leverage growth in existing markets by becoming more aggressive in sales.
Q: The margin in Europe was slightly down. Is there a specific reason for this? A: Matti Jakel, CFO, noted that the slight margin decrease is a normal fluctuation due to contract and product mix variations. He emphasized that the overall performance in Europe, when combined with the technologies segment, remains strong.
Q: Can you discuss the performance and profitability of the technologies segment, particularly in nuclear and life sciences? A: Thomas Schulz, CEO, highlighted that the technologies segment, especially in pharma and biopharma, has seen significant revenue growth. The improvements in this segment are attributed to strategic enhancements made over the past few years.
Q: With order wins flat organically, can you comment on your order win rate and expectations for Q4? A: Thomas Schulz, CEO, explained that order intake can fluctuate due to client permitting and timing. He emphasized the importance of year-to-date order intake and backlog growth, which align with the company's strategic targets.
Q: Are there any hiring challenges, and is staffing a limiting factor for growth? A: Thomas Schulz, CEO, stated that while there are challenges in remote areas, Bilfinger remains an attractive employer, especially in the blue-collar segment, and does not face significant staffing issues.
Q: How does the US government shutdown impact your E&M International segment? A: Matti Jakel, CFO, mentioned that about 20-25% of revenue in the international segment comes from government entities. While the shutdown has delayed some activities, improvements are expected in Q2 2026 as operations normalize.
Q: Can you clarify the impact of recent acquisitions on sales and EBITA? A: Matti Jakel, CFO, noted that two acquisitions contributed approximately 35-40 million to order intake and revenue, with above-average EBITA margins. The third acquisition will add to Q4 results but will not significantly impact overall figures.
Q: Why consider larger M&A transactions in North America or the Middle East? A: Thomas Schulz, CEO, explained that Bilfinger is currently subscale in these regions. Larger acquisitions would help achieve the scale needed to secure profitable long-term agreements and reduce administrative burdens.
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
